{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3"},{"groupId":"OG001","value":"78.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"Progression free survival was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurs first. Progression was based on tumour assessment made by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria (for participants with measurable disease), and for those with non-measurable disease presence or absence of lesions was noted.","groups":[{"description":"Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 mg/m\\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 q4w OR topotecan 4 mg/m\\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\\^2 dose could have been administered over 30 minutes on Days 1-5 q3w) OR PLD 40 mg/m\\^2 as a 1 mg/min infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion). Depending on chosen chemotherapy, pre-medication was implemented according to local practices.","id":"OG000","title":"Chemotherapy"},{"description":"Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 mg/m\\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 q4w OR topotecan 4 mg/m\\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\\^2 dose could have been administered over 30 minutes on Days 1-5 q3w) OR PLD 40 mg/m\\^2 as a 1 mg/min infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion). Depending on chosen chemotherapy, pre-medication was implemented according to local practices. The chosen chemotherapy was combined with bevacizumab 10 mg/kg IV q2w (or bevacizumab 15 mg/kg q3w if used in combination with topotecan 1.25 mg/m\\^2 on Days 1-5 on a q3w schedule). The initial bevacizumab infusion was over 90 minutes, with subsequent infusions over 60 minutes and then 30 minutes, as tolerated.","id":"OG001","title":"Chemotherapy + Bevacizumab"}],"paramType":"NUMBER","populationDescription":"ITT Population: All participants randomized to study treatment, irrespective of whether or not the assigned treatment was actually received. For all efficacy analyses, participants were grouped according to the treatment assigned at randomization","reportingStatus":"POSTED","timeFrame":"Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011","title":"Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}